Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Prolonged antigen storage endows merocytic dendritic cells with enhanced capacity to prime anti-tumor responses in tumor-bearing mice.

Reboulet RA, Hennies CM, Garcia Z, Nierkens S, Janssen EM.

J Immunol. 2010 Sep 15;185(6):3337-47. doi: 10.4049/jimmunol.1001619. Epub 2010 Aug 18.

2.

Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.

Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R.

J Immunol. 2003 Dec 1;171(11):5940-7.

3.

Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.

Johannsen A, Genolet R, Legler DF, Luther SA, Luescher IF.

J Immunol. 2010 Sep 15;185(6):3445-55. doi: 10.4049/jimmunol.1001397. Epub 2010 Aug 23.

4.

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.

Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F.

Cancer Immunol Immunother. 2004 Nov;53(11):963-77. Epub 2004 May 14.

PMID:
15146294
5.

Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.

Stoitzner P, Green LK, Jung JY, Price KM, Atarea H, Kivell B, Ronchese F.

Cancer Immunol Immunother. 2008 Nov;57(11):1665-73. doi: 10.1007/s00262-008-0487-4. Epub 2008 Mar 1.

PMID:
18311487
6.

Cutting edge: merocytic dendritic cells break T cell tolerance to beta cell antigens in nonobese diabetic mouse diabetes.

Katz JD, Ondr JK, Opoka RJ, Garcia Z, Janssen EM.

J Immunol. 2010 Aug 15;185(4):1999-2003. doi: 10.4049/jimmunol.1001398. Epub 2010 Jul 19.

7.

Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.

Hennies CM, Reboulet RA, Garcia Z, Nierkens S, Wolkers MC, Janssen EM.

Clin Exp Immunol. 2011 Mar;163(3):381-91. doi: 10.1111/j.1365-2249.2010.04305.x. Epub 2011 Jan 14.

8.
9.

ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.

Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, Koernig S, Morelli AB, Clausen BE, Dauer M, Eigler A, Anz D, Bourquin C, Maraskovsky E, Endres S, Schnurr M.

J Immunol. 2011 Jul 1;187(1):55-63. doi: 10.4049/jimmunol.1004114. Epub 2011 May 25.

10.
11.

Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming.

Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M, Spada M, Belardelli F, Gabriele L, Schiavoni G.

J Immunol. 2011 May 1;186(9):5142-50. doi: 10.4049/jimmunol.1004163. Epub 2011 Mar 25.

12.

Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.

Ribas A, Wargo JA, Comin-Anduix B, Sanetti S, Schumacher LY, McLean C, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS.

J Immunol. 2004 Apr 15;172(8):4762-9.

13.

β-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8⁺ T cells.

Liang X, Fu C, Cui W, Ober-Blöbaum JL, Zahner SP, Shrikant PA, Clausen BE, Flavell RA, Mellman I, Jiang A.

J Leukoc Biol. 2014 Jan;95(1):179-90. doi: 10.1189/jlb.0613330. Epub 2013 Sep 10.

PMID:
24023259
14.

Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.

Preynat-Seauve O, Contassot E, Schuler P, French LE, Huard B.

Melanoma Res. 2007 Jun;17(3):169-76.

PMID:
17505262
15.

Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets.

Tel J, Schreibelt G, Sittig SP, Mathan TS, Buschow SI, Cruz LJ, Lambeck AJ, Figdor CG, de Vries IJ.

Blood. 2013 Jan 17;121(3):459-67. doi: 10.1182/blood-2012-06-435644. Epub 2012 Dec 4.

16.

Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.

Côté AL, Zhang P, O'Sullivan JA, Jacobs VL, Clemis CR, Sakaguchi S, Guevara-Patiño JA, Turk MJ.

J Immunol. 2011 Jan 1;186(1):275-83. doi: 10.4049/jimmunol.1001308. Epub 2010 Nov 24.

17.

Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.

Hu HM, Winter H, Urba WJ, Fox BA.

J Immunol. 2000 Oct 15;165(8):4246-53.

18.
19.

CpG promotes cross-presentation of dead cell-associated antigens by pre-CD8α+ dendritic cells [corrected].

de Brito C, Tomkowiak M, Ghittoni R, Caux C, Leverrier Y, Marvel J.

J Immunol. 2011 Feb 1;186(3):1503-11. doi: 10.4049/jimmunol.1001022. Epub 2010 Dec 27. Erratum in: J Immunol. 2011 Jun 15;186(12):7272.

20.

Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.

Wei J, Waithman J, Lata R, Mifsud NA, Cebon J, Kay T, Smyth MJ, Sadler AJ, Chen W.

J Immunol. 2010 Nov 15;185(10):6013-22. doi: 10.4049/jimmunol.1002129. Epub 2010 Oct 18.

Supplemental Content

Support Center